Vietnam Acute Lymphocytic Leukemia (ALL) Therapeutics Market Report 2022 to 2030

Vietnam Acute Lymphocytic Leukemia (ALL) Therapeutics Market Analysis

$ 3999

The Vietnam Acute Lymphocytic Leukemia (ALL) Therapeutics Market was valued at US $17 Mn in 2022, and is predicted to grow at (CAGR) of 8.03% from 2023 to 2030, to US $31 Mn by 2030. The key drivers of this industry include a surge in the incidence of acute lymphocytic leukemia cases, the adoption of novel therapies, increased government initiatives, and other factors. The industry is primarily dominated by players such as Hau Giang, Vietnam Pharma, Pfizer, Novartis, among others

ID: IN10VNPH423 CATEGORY: Pharmaceuticals GEOGRAPHY: Vietnam AUTHOR: Riddhi Solanki

Buy Now

Vietnam Acute Lymphocytic Leukemia (ALL) Therapeutics Market Analysis

The Vietnam Acute Lymphocytic Leukemia (ALL) Therapeutics Market is at around US $17 Mn in 2022 and is projected to reach US $31 Mn in 2030, exhibiting a CAGR of 8.03% during the forecast period.

Acute Lymphocytic Leukemia (ALL) is characterized by the rapid multiplication of immature white blood cells, known as lymphoblasts, within the bone marrow. This condition typically arises due to a genetic mutation affecting developing lymphocytes, resulting in the accumulation of undifferentiated lymphoid cells. Symptoms include recurrent infections, enlarged lymph nodes, weight loss, bone pain, and other manifestations. Medical management of ALL requires a comprehensive treatment plan lasting months or even years, including therapies such as chemotherapy, targeted treatments, CAR-T cell immunotherapy, and, in extreme cases, stem cell transplantation. These advancements in treatment substantially increase the chances of a cure, often achieving success rates of up to 80% in both adults and children.

The incidence of ALL is about 1/1,00,000 individuals in Vietnam. Every year, 700 new cases are diagnosed in children. The market is therefore driven by major factors like the surge in the incidence of ALL cases, the adoption of novel therapies like policy, and increased government support in the therapeutics industry. However, conditions such as high costs of advanced treatment, affordability of novel therapeutics, and others hinder the growth and potential of the market.

Market Dynamics

Market Growth Drivers

Increased incidence of cases: The incidence of ALL is 1/1,00,000 individuals, with 700 newly diagnosed cases annually affecting children in Vietnam. This incidence is expected to increase in the forecasted period, driving market expansion.

Adoption of novel therapies: The Vietnamese government is actively engaging in reforms to support cost-effective and clinically effective treatment to paediatric and adult ALL patients. Emerging targeted medications such as blinatumomab and Polatuzumab Vedotin (Polivy) are progressively garnering attention, presenting personalized and potentially curative alternatives.

Increased government support: The Vietnamese government has recently started extending its support to improve leukemia care in the country, which includes initiatives such as the National Cancer Control Program to prioritize leukemia treatment, including ALL.

Market Restraints

Limited access: There's a need for focused care for underprivileged children, addressing sociodemographic and socioeconomic gaps. The public health insurance system remains insufficiently developed. There exist disparities between access of care in rural and urban areas where novel treatment options remain inaccessible to majority of Vietnamese population

Affordability: Finding a middle ground between embracing innovative, potentially curative treatments such as CAR-T and ensuring affordability for all patients poses a challenge for healthcare policymakers. Affordability remains a substantial obstacle for numerous patients, calling for cost-efficient solutions and additional policy adjustments.

Limited expertise: Limited numbers of skilled haematologists and oncologists create barriers to accessing specialized leukemia care and potential delays in accessing advanced therapies or clinical trials for leukemia patients.

Healthcare Policies and Regulatory Landscape

Vietnam's healthcare policy and regulatory structure involve various significant authorities and agencies. The primary entity responsible for healthcare regulations and licensing in Vietnam is the Drug Administration of Vietnam (DAV) under the Ministry of Health (MOH). The MOH is accountable for devising national health policies, coordinating medical and healthcare reform, and supervising healthcare services.

Acquiring a license for healthcare products in Vietnam requires adherence to the regulations established by the MOH. For pharmaceuticals and medical devices, companies must secure registration and marketing authorization from the MOH. This process involves submitting technical and scientific data to validate the product's safety, quality, and effectiveness.

Vietnam’s healthcare policy and regulatory framework involve numerous authorities and agencies, with the MOH holding a pivotal role in healthcare product regulation. Both the public and private healthcare sectors in the country offer diverse opportunities for companies operating within the healthcare industry. Both the public and private healthcare sectors in the country offer diverse opportunities for companies operating within the healthcare industry.

Competitive Landscape

Key Players

DHG Pharma
Vietnam Pharma
Pymepharco
DHG Hatipharma
Sanofi
Novartis
Roche
Merck
Pfizer
Amgen

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Vietnam Acute Lymphocytic Leukemia (ALL) Therapeutics Market Segmentation

By Type

Paediatrics
Adults

By Drug

Hyper CVAD regimen
Linker Regimen
Nucleoside Metabolic Inhibitors
Targeted drugs and Immunotherapy
CALGB 811 Regimen

By Cell

B Cell ALL
T Cell ALL
Philadelphia Chromosome

By Therapy

Chemotherapy
Targeted therapy
Radiation therapy
Stem Cell Transplantation

By Distribution channel

Hospital Pharmacy
Retail Pharmacy
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.